Calcitonin

Results: 99



#Item
41Calcitonin  –  Mary  Carol  Jennings  –  March  5  –  FDA  Joint  Advisory  Committee  meeting   My name is Dr. Mary Carol Jennings and I speak today on behalf of the Natio

Calcitonin  –  Mary  Carol  Jennings  –  March  5  –  FDA  Joint  Advisory  Committee  meeting   My name is Dr. Mary Carol Jennings and I speak today on behalf of the Natio

Add to Reading List

Source URL: npalliance.org

Language: English - Date: 2013-10-09 15:48:22
42article December 2007 䡠 Vol. 9 䡠 No. 12 Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density

article December 2007 䡠 Vol. 9 䡠 No. 12 Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density

Add to Reading List

Source URL: www.nature.com

Language: English - Date: 2012-01-04 14:10:30
43PHARMACEUTICAL COMPANY INC.

PHARMACEUTICAL COMPANY INC.

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2005-10-31 09:12:19
44Microsoft PowerPoint - Miacalcin_(calcitonin_salmon)_FINAL_3[removed]

Microsoft PowerPoint - Miacalcin_(calcitonin_salmon)_FINAL_3[removed]

Add to Reading List

Source URL: www.fda.gov

Language: English
452014 PLENARY SPEAKERS Plenary Session I– Sunday, June 22, 2014 Dr. Ting-Kai Li Lectureship Karl Mann, M.D., Ph.D Karl Mann received his MD from Mainz University and his PhD from Tuebingen University. He is a board cert

2014 PLENARY SPEAKERS Plenary Session I– Sunday, June 22, 2014 Dr. Ting-Kai Li Lectureship Karl Mann, M.D., Ph.D Karl Mann received his MD from Mainz University and his PhD from Tuebingen University. He is a board cert

Add to Reading List

Source URL: www.rsoa.org

Language: English - Date: 2014-03-27 23:41:11
46Laboratory Fee Schedule Provider Specialty 069 The inclusion of a rate on this table does not guarantee that a service is covered. Please refer to the Medicaid Billing Guide and the Medicaid and Health Choice Clinical Co

Laboratory Fee Schedule Provider Specialty 069 The inclusion of a rate on this table does not guarantee that a service is covered. Please refer to the Medicaid Billing Guide and the Medicaid and Health Choice Clinical Co

Add to Reading List

Source URL: www.ncdhhs.gov

Language: English - Date: 2012-01-18 16:30:43
47Laboratory Fee Schedule Provider Specialty 069 The inclusion of a rate on this table does not guarantee that a service is covered. Please refer to the Medicaid Billing Guide and the Medicaid and Health Choice Clinical Co

Laboratory Fee Schedule Provider Specialty 069 The inclusion of a rate on this table does not guarantee that a service is covered. Please refer to the Medicaid Billing Guide and the Medicaid and Health Choice Clinical Co

Add to Reading List

Source URL: www.ncdhhs.gov

Language: English - Date: 2012-03-12 09:40:27
48Laboratory Fee Schedule Provider Specialty 069 The inclusion of a rate on this table does not guarantee that a service is covered. Please refer to the Medicaid Billing Guide and the Medicaid and Health Choice Clinical Co

Laboratory Fee Schedule Provider Specialty 069 The inclusion of a rate on this table does not guarantee that a service is covered. Please refer to the Medicaid Billing Guide and the Medicaid and Health Choice Clinical Co

Add to Reading List

Source URL: www.ncdhhs.gov

Language: English - Date: 2012-07-02 11:51:03
49An Update on Novel Therapies for Advanced Thyroid Cancer: When to Start and What to Use Case Discussions - Presenter: Mimi I. Hu, MD Learning Objectives: - Understand when to consider novel therapies for advanced thyroid

An Update on Novel Therapies for Advanced Thyroid Cancer: When to Start and What to Use Case Discussions - Presenter: Mimi I. Hu, MD Learning Objectives: - Understand when to consider novel therapies for advanced thyroid

Add to Reading List

Source URL: www.thyroid.org

Language: English - Date: 2014-04-02 19:28:42
50Medullary Thyroid Carcinoma: New Therapies and Trials Matthew D. Ringel, MD Ralph W. Kurtz Chair and Professor of Medicine Director, Division of Endocrinology, Diabetes, and Metabolism The Ohio State University College o

Medullary Thyroid Carcinoma: New Therapies and Trials Matthew D. Ringel, MD Ralph W. Kurtz Chair and Professor of Medicine Director, Division of Endocrinology, Diabetes, and Metabolism The Ohio State University College o

Add to Reading List

Source URL: www.thyroid.org

Language: English - Date: 2014-01-11 17:19:53